EUROSURVEILLANCE 16/03/17 Use of WHONET-SaTScan system for simulated real-time detection of antimicrobial resistance clusters in a hospital in Italy, 2012 to 2014. A Natale 1 , J Stelling 2 , M Meledandri 3 , LA Messenger 4 , F D'Ancona 5 6 + Author affiliations Citation style for this article: Natale A, Stelling J, Meledandri M, Messenger LA, D'Ancona F.
Use of WHONET-SaTScan system for simulated real-time detection of antimicrobial resistance clusters in a hospital in Italy, 2012 to 2014. Euro Surveill. 2017;22(11):pii=30484. DOI: Received:01 February 2016; Accepted:21 August 2016. PLOS 04/05/16 High Prevalence of Infectious Diseases and Drug-Resistant Microorganisms in Asylum Seekers Admitted to Hospital; No Carbapenemase Producing Enterobacteriaceae until September 2015.
Abstract Introduction The current refugee crisis emphasizes the need for information on infectious diseases and resistant microorganisms in asylum seekers with possible consequences for public health and infection control.
Methods We collected data from asylum seekers admitted to our university hospital or who presented at the Emergency Department (n = 273). We collected general and demographic characteristics including country of origin, the reason of presentation, and the screening results of multi-drug resistant organisms. Results 67% of the patients were male with a median age of the study group of 24 years (IQR 15–33); 48% of the patients had an infectious disease—predominantly malaria with P. vivax or tuberculosis. EMA - JUNE 2016 - Eurobarometer survey on the use and perceptions of antibiotics in the EU. The emerging and steady increase of microbes that are resistant to antimicrobial treatments has become a global public health concern that threatens the effective treatment of infectious diseases.
Combatting this threat, particularly resistance to antibiotics, is a high priority for the European Medicines Agency (EMA) and the European medicines regulatory network. Antimicrobial resistance is when a microbe evolves to become more or fully resistant to antimicrobials which previously could treat it. Antimcirobials include antibiotics, which kill or inhibit the growth of bacteria. Download image in PDF format A well-known example of a bacterium that is resistant to a number of antibiotics is meticillin-resistant Staphylococcus aureus (MRSA), which has caused infections that are difficult to treat across the European Union (EU).
Infections by multidrug-resistant bacteria are estimated to cause 25,000 deaths in the EU every year. Agency role EMA Executive Director, Prof. EUROSURVEILLANCE 11/08/16 Risk-adjusted antibiotic consumption in 34 public acute hospitals in Ireland, 2006 to 2014. A Oza 1 , F Donohue 2 , H Johnson 2 , R Cunney 1 + Author affiliations Citation style for this article: Oza A, Donohue F, Johnson H, Cunney R.
Risk-adjusted antibiotic consumption in 34 public acute hospitals in Ireland, 2006 to 2014. Euro Surveill. 2016;21(32):pii=30312. DOI: Received:16 September 2015; Accepted:30 May 2016. EUROPE - JUIN 2016 - Eurobarometer results on Antimicrobial Resistance awareness. Antimicrobial Resistance (AMR) is the ability of microorganisms to resist antimicrobial treatments, especially antibiotics.
AMR not only has a direct impact on human and animal health - due to the failure in the treatment of infectious diseases - but also carries a heavy economic cost. AMR is a natural phenomenon but an accumulation of factors, including excessive and inappropriate use of antimicrobial medicines on humans and animals and poor infection control practices, transformed AMR into a serious threat to public health worldwide. This leads to: BFR 19/01/15 The challenge of antimicrobial resistance - a holistic consideration and the latest insights into risk perception. The BfR organises a forum on antimicrobial resistance in the context of the International Green Week in Berlin Antimicrobial resistance increasingly poses a challenge to public health worldwide.
When antibiotics are used, for example in a hospital or a production animal facility, this can assist the spread of resistant bacteria. It is becoming more and more difficult to treat infectious diseases with existing antibiotics. CDC EID - - Avril 2014 - Au sommaire notamment: High Rates of Antimicrobial Drug Resistance Gene Acquisition after International Travel, the Netherlands. Author affiliations: Maastricht University Medical Center, Maastricht, the Netherlands (C.J.H. von Wintersdorff, J.
Penders, E.E. Stobberingh, A.M.L. Oude Lashof, C.J.P.A. Hoebe, P. Savelkoul, P.H.M. Suggested citation for this article. ECDC 17/11/14 Resistance to last-line antibiotics continues to cause concern in Europe. On the occasion of the 7th European Antibiotic Awareness Day, the European Centre for Disease Prevention and Control (ECDC) is releasing its latest EU-wide data on antibiotic resistance (EARS-Net annual report and interactive database).
Carbapenems are a major last-line class of antibiotics used to treat healthcare-associated infections. Although carbapenem resistance remains at relatively low levels for most countries, ECDC data show an increase of carbapenem resistance in Klebsiella pneumoniae from a population-weighted EU average percentage of 4.6% in 2010 to 8.3% in 2013. For the first time in 2013, ECDC monitored resistance to polymyxins (e.g. colistin) in Klebsiella pneumoniae across Europe. EUROPE 13/05/14 EU and US progress in the fight against antimicrobial resistance.
Public Health (13-05-2014) EU and US progress in the fight against antimicrobial resistance Today, the European Commission (EC) and the US Department of Health and Human Services (HHS) publish a progress report on the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR).
The report outlines the advances made during the first TATFAR implementation period of 2011 to 2013, and renews the commitment of US and EU health authorities to pursue specific goals in their joint battle against antimicrobial resistance (AMR). Notable outcomes of TATFAR activities for the reporting period include: Why a Transatlantic Taskforce? EUROSURVEILLANCE 16/10/14 European Antibiotic Awareness Day: a five-year perspective of Europe-wide actions to promote prudent use of antibiotics. Following the European Union (EU) Council Recommendation on prudent use of antimicrobial agents in human medicine in 2001, and the success of national campaigns, i.e.
Belgium and France, the European Centre for Disease Prevention and Control (ECDC) decided to establish the European Antibiotic Awareness Day (EAAD) on 18 November as platform to support national campaigns across Europe. This article provides an overview of EAAD tools, materials, and activities developed during the first five years. It shows that EAAD has been successful due to good cooperation between ECDC and national institutions, strong political and stakeholder support and evidence-based development of campaign materials. EAAD has provided a platform for pre-existing national campaigns and encouraged similar campaigns to develop where neither political support had been secured, nor financial support had been available.
Introduction The emergence and spread of antibiotic resistance, is recognised as a global problem. EUROSURVEILLANCE 15/01/15 Widespread implementation of EUCAST breakpoints for antibacterial susceptibility testing in Europe. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) was established to harmonise clinical antimicrobial breakpoints and to define breakpoints for new agents in Europe. Data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) external quality assessment (EQA) exercises from 2009 to 2012, from the United Kingdom External Quality Assessment Scheme (UK NEQAS) from November 2009 to March 2013 and data collected by EUCAST through a questionnaire in the first quarter of 2013 were analysed to investigate implementation of EUCAST guidelines in Europe. A rapid change to use of EUCAST breakpoints was observed over time. Figures for implementation of EUCAST breakpoints at the end of the studied period were 61.2% from EARS-Net data and 73.2% from UK NEQAS data.
ESCMID has remained the administrative, financial and scientific platform of EUCAST throughout. Analysed data sources Data presented here are taken from three different sources. Results Table. EUROPE - NOV 2013 - EUROBAROMETRE SPECIAL 407 - LA RÉSISTANCE AUX ANTIMICROBIENS. Int J Public Health (2010) 55:469–478 Socioeconomic determinants of outpatient antibiotic use in Europe. Objectives Outpatient antibiotic consumption widely varies across Europe. The investigation of the causes of such variation may help to identify interventions that would improve the efficient use of antibiotics.
The aim of this study was to assess the impact of socioeconomic determinants and the role played by information about bacterial resistance. Methods Comparable data on systemically administered antibiotics and socioeconomic determinants in 17 European countries were available between 2000 and 2005. Results The population income, demographic structure, density of general practitioners and their remuneration method appeared to be significant determinants of antibiotic consumption. Conclusions The study confirms that socioeconomic factors should be taken into account while explaining differences in outpatient antibiotic use across countries.
Journal of Antimicrobial Chemotherapy (2007) 59, 132–139 Third Belgian multicentre survey of antibiotic susceptibility of anaero. ESGARS - "European Recommendations for Antimicrobial Resistance Surveillance", Annual Report 2005. ESCMID: EUCAST. ESAC - EUROPEAN SURVEILLANCE OF ANTIMICROBIAL CONSUMPTION. EMA 25/07/11 European Medicines Agency publishes new strategy on combating antimicrobial resistance. The European Medicines Agency has published a new strategy for 2011-2015 aimed at combating the threat of antimicrobial resistance that may arise from the use of antimicrobials (mainly antibiotics) in animals. The strategy, prepared by the Committee for Medicinal Products for Veterinary Use (CVMP), promotes the continued availability of effective antimicrobials for use in animals while acting to minimise risks to animals or humans arising from their use. The role of the Agency is to foster the implementation of this strategy over the next five years.
The Agency published the strategy for consultation in March 2011 and comments received as a result of the consultation were taken into consideration by the CVMP. An overview of the comments received has also been published. This strategy complements, and forms part of, the wider Community Animal Health Strategy which provides a framework for animal health and welfare measures until 2013. The Plymouth Student Scientist, 2011, 4, (2), 252-266  Current and emerging issues in nosocomial infections and antibiotic.